Rodent Pharmacokinetic (PK) Studies

Understand Drug Exposure Before Advancing Development

A promising compound must achieve sufficient exposure in vivo to demonstrate efficacy and support further development. Rodent pharmacokinetic (PK) studies provide essential insight into how a drug candidate is absorbed, distributed, metabolized, and eliminated, enabling researchers to evaluate systemic exposure, bioavailability, clearance, half-life, and tissue distribution early in drug discovery.

At WuXi Biology and Testing, our integrated DMPK platform supports comprehensive rodent PK studies in mice and rats across multiple therapeutic modalities and administration routes. Combined with bioanalysis and in vitro ADME data, these studies provide the pharmacokinetic foundation for lead optimization, candidate selection, PK/PD analysis, and IND-enabling development.

300K+

In Vitro ADME Studies Annually

20K+

In Vivo Studies Annually

1,500+

Successful IND Filings

Why Are Rodent PK Studies Critical in Drug Discovery?

Rodent PK studies are often the first in vivo experiments used to determine whether a compound has the pharmacokinetic profile needed to advance. They bridge the gap between in vitro ADME assays and efficacy, toxicology, and translational studies by revealing how a compound behaves in a living organism.

Rodent PK studies help answer key development questions, including:

  • Does the compound achieve sufficient systemic exposure?
  • Is oral bioavailability adequate for the intended dosing strategy?
  • Is clearance too rapid to maintain therapeutic concentrations?
  • Does the half-life support the desired dosing interval?
  • Does exposure increase proportionally with dose?
  • Which compound should progress during lead optimization?
  • How well do in vitro ADME results translate to in vivo pharmacokinetics?

These data reduce uncertainty during drug discovery and support more informed development decisions.

Designing an Effective Rodent PK Study

The design of a rodent PK study depends on the scientific objective, therapeutic modality, and stage of development. Careful planning helps generate meaningful pharmacokinetic data while maximizing study efficiency.

Species Selection

Rodent PK studies are commonly performed in mice and rats, with species selected according to disease model, pharmacology, safety assessment, therapeutic modality, and translational objectives. Rodent PK studies are commonly performed in:

  • Mouse
  • Rat

Route of Administration

Common administration routes include:

  • Intravenous (IV)
  • Oral (PO)
  • Subcutaneous (SC)
  • Intraperitoneal (IP)
  • Intramuscular (IM)
  • Intranasal (IN)
  • Other specialized routes when appropriate

Comparing IV and oral dosing enables determination of absolute oral bioavailability and helps distinguish absorption limitations from systemic clearance.

Sampling Strategy

Appropriate sampling schedules are essential for accurately characterizing:

  • Cmax
  • Tmax
  • AUC
  • Clearance
  • Half-life
  • Volume of distribution

Sparse, serial, and cassette study designs can be selected based on study objectives and compound availability.

Bioanalytical Support

Reliable PK interpretation depends on accurate bioanalysis. Sensitive LC–MS/MS methods quantify drug concentrations in plasma and other biological matrices, supporting robust noncompartmental or compartmental PK analyses.

Key Pharmacokinetic Parameters and Their Meaning

Rodent PK studies generate a range of pharmacokinetic parameters that characterize a drug's exposure and disposition in vivo. Together, these parameters help researchers evaluate absorption, distribution, metabolism, and elimination (ADME), compare drug candidates, optimize dosing strategies, and make informed decisions throughout drug development.

Rodent PK Studies

Integrating Rodent PK with DMPK Studies

Rodent PK studies identify exposure outcomes, while complementary ADME assays help explain the mechanisms responsible for those outcomes. Our integrated workflow combines rodent PK with:

  • Metabolic Stability
  • Plasma Protein Binding
  • Solubility
  • Permeability
  • CYP Inhibition and Induction
  • Metabolite Identification
  • Tissue Distribution
  • Bioanalysis
  • PK/PD Modeling

Integrating these datasets helps identify the factors driving exposure, optimize drug candidates, and improve translation from discovery to preclinical development.

Rodent PK Applications Throughout Drug Development

Hit Identification

  • Confirm measurable in vivo exposure
  • Compare early compounds

Lead Optimization

  • Improve pharmacokinetic properties
  • Guide medicinal chemistry
  • Evaluate formulation strategies

Candidate Selection

  • Compare exposure profiles
  • Support dose selection
  • Assess translational potential

IND-Enabling Development

  • Inform toxicology study design
  • Support PK/PD analysis
  • Enable human PK prediction through IVIVE and PBPK
Explore Solutions

Explore Solutions for Your Program

Explore solutions by development phase, drug modality, therapeutic area, or integrated discovery needs.

Get A Quote

Get a Quote

Ready to plan your next study? Share your program needs with our team for a tailored estimate.

Frequently Asked Questions

Get a Quote